4 quarters of 13F filings · Δ columns show change vs prior quarter
Quarter
Inst. Holders
Δ Holders
Ownership %
Δ Ownership
Total 13F Value
Δ Value
Q2 2026
63
3.1%
73.58%
+2.09 pp
$447M
12%
Q1 2026
65
+23%
71.49%
1.30 pp
$508M
32%
Q4 2025
53
+29%
72.79%
+1.87 pp
$746M
+15%
Q3 2025
41
—
70.92%
—
$647M
—
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
BBOT — Frequently Asked Questions
Quick answers to the most common questions about buying BBOT stock.
What percentage of BBOT is owned by institutions?
Based on Q2 2026 13F filings, institutional ownership of BridgeBio Oncology Therapeutics Inc. stands at 73.6%, held across 63 reporting institutions.
Who is the largest institutional holder of BBOT?
Cormorant Asset Management, LP is the largest reported institutional holder of BBOT, with approximately 17,878,594 shares worth $0.14B as of Q2 2026.
Is BBOT a hedge fund favorite?
Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of BBOT, including CITADEL ADVISORS LLC.
What is BBOT's Smart Money Score?
Our composite Smart Money Score for BBOT is 54 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in BBOT — a direct measure of their conviction.
16 institutions opened new positions in BBOT during Q2 2026, while 18 fully exited. 12 added to existing positions and 35 trimmed.
How is institutional ownership of BBOT changing?
BBOT institutional ownership rose by 2.09 percentage points quarter-over-quarter, with a net change of -2 holders.
How concentrated is BBOT ownership among the top holders?
The top 10 institutions account for 75.3% of all reported 13F value in BBOT, and the top 25 account for 96.0%.
Where does this BBOT institutional ownership data come from?
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
BridgeBio Oncology Therapeutics Inc. (BBOT) Institutional Ownership